32 results about "Microdosing" patented technology

A volume sensor-free microdosing device comprises a pressure chamber which is at least partly delimited by a displacer, an actuating device for actuating the displacer, the volume of the pressure chamber being adapted to the changed by actuating the displacer, a media reservoir which is in fluid communication with the pressure chamber, an outlet opening which is in fluid communication with the pressure chamber, and a control mechanism. The control mechanism drives the microdosing device in such a way that a small change of volume of the pressure chamber volume is effected per unit time by a movement of the displacer from a first position to a predetermined second position, the second position of the displacer defining a larger volume of the pressure chamber than the first position, so as to suck a fluid volume into the pressure chamber, and that, in a second phase, a large volume change of the pressure chamber volume is effected per unit time by a movement of the displacer from the second position to the first position, so as to eject a defined fluid volume from the outlet opening in this way.

The invention relates to an insulin pump (1) with an infusion set adapter (21) having a diaphragm (7) exposed to the liquid path (2). Arranged in the housing (20) of the insulin pump (1) is a measurement arrangement comprising emitter (4) and sensor (5), by means of which a bowing of the diaphragm (7) following a change in the liquid pressure in the liquid path (2) can be detected without contact, for recognizing an occlusion in the liquid path (2). This yields the advantage that an accurate and delay-free occlusion recognition with low system cost becomes possible.

The present invention provides accelerated detoxification methods for the treatment of a substance abuse-related condition in a subject. A method of the present invention may comprise administering to the subject an effective amount of at least one sedative (e.g, clonidine, diazepam, or olanzapine) and a micro-dose of an opioid antagonist (e.g., naltrexone or naloxone) for at least one day; optionally administering a small dose of an opiate, and administering to the subject a detoxifying amount of a second opioid antagonist (e.g., naloxone); and may further comprise administering to the subject a third opioid antagonist (such as, naltrexone) for an extended period of time (e.g., 12 months).

A microdosing device includes a dosing chamber which at least temporarily receives a quantity of liquid, and to which at least one dispensing opening is assigned. A vibration unit is operatively connected to at least one boundary surface of the dosing chamber in order to cause this boundary surface to oscillate for the purpose of a dispensing operation.

At least two admission channels spaced apart from one another are provided on the dosing chamber.

A fluid sample dispenser includes a microdosing device for outputting, during an activation state, a fluid sample at a fluid sample outlet to the environment, wherein the microdosing device is placeable adjacent to a person's nose so that a distance between the outlet of the microdosing device and a nostril of the person's nose is within a predefined range, and a microdosing driver unit for adjusting a dosing rate of the scent sample output at the scent sample outlet by selectively activating the microdosing device.

A microdosing device for dosing smallest quantities of a medium, having an inlet device, an outlet device, a pump device and a media duct that leads from the inlet device to the outlet device, the inlet device having an inlet opening and an inlet valve having an inlet valve piston, and the outlet device having an outlet opening and an outlet valve having an outlet valve piston, and the pump device having a pump piston. The inlet valve piston, the outlet valve piston and the pump piston are situated on a common diaphragm layer. The microdosing device has the advantage that it is able to be produced in a simple and cost-effective manner.

The present invention discloses a method to recover and restore dendritic and synaptic neuron connections that have been degraded or destroyed by neurodegenerative diseases. In the present invention tryptamines are used to induce neuro plasticity and restore both dendritic density and synaptic connections of neurons in the brain. In the preferred embodiment LSD given in micro doses can induce dendritic and synaptic genesis in neuronal networks and improve the quality of life of people with neurodegenerative diseases such as Alzheimer's, Huntington's, Multiple Sclerosis, Parkinson's and Frontotemporal dementia.

The present disclosure relates to the transdermal administration of psychedelics, such as psilocybin, psilocin, lysergic acid diethylamine (LSD), and/or ibogaine, and derivatives of these compounds, for the treatment and/or prevention and/or control of severe depression (treatment resistant), major depressive disorder, obsessive-compulsive disorder, quitting smoking, alcohol addiction, cocaine addiction, opioid addiction, anxiety (stress), adult ADHD, cluster headaches, and cancer related or other end-of-life psychological distress.

A method of dosing and treating patients with a psychedelic, by administering a psychedelic at a dose of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, and producing maximum positive subjective acute effects that are known to be associated with more positive long-term outcomes and minimizing negative acute effects. A method of determining a dose of a psychedelic for an individual, by administering a dose of a psychedelic to the individual of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, determining positive acute effects and negative acute effects in the individual, and adjusting the dose to provide more positive acute effects than negative acute effects in the individual. Methods of treating psychiatric conditions or providing therapy. A method of defining therapeutic doses of a psychedelic in clinical trials. A method of monitoring individuals for depression after treatment with LSD.

A microdosing device with a dosing chamber for the at least temporary reception of a liquid quantity, and with which is associated at least one discharge opening is provided. A vibrating unit in operative connection with at least one boundary surface of the dosing chamber is provided in order to vibrate the same for a discharge process, and with a delivery function unit connected to the vibrating unit for activating the latter during a delivery time period. A drying function unit is additionally provided and can be activated in time-separated manner with respect to the delivery function unit in order to free the dosing chamber from liquid residues.

Techniques for generating radiotherapy treatment plan parameters are provided. The technology comprises the following steps: receiving radiotherapy treatment plan information; processing the radiotherapy treatment plan information to estimate one or more radiotherapy treatment plan parameters based on processing of an output of the sub-processing dependent on the derivative of the estimated dose calculation; and generating a radiotherapy treatment plan using the estimated one or more radiotherapy treatment plan parameters.

Means and methods for dispensing small amounts of liquid from multi-channel microdispensing devices, suitable for use in automatic processing in biological assays and for the cultivation of cells andtissues, by means of optical control of the dosed liquid by specific light barrier units.

The invention relates to a biological dose calculation method for boron neutron capture therapy (BNCT). According to the method disclosed by the invention, accurate measurement of the tumor cell scale and tumor/normal tissue vessel boron concentration distribution is realized based on a neutron autography technology; according to different boron drug distribution characteristics, neutron energy spectra and tissue material characteristics, the corresponding relationship between boron distribution and neutron energy and the relative biological effect (RBE) or the complex biological effect (CBE) of all ray components of the BNCT is constructed through Monte Carlo simulation and a microdosimetry physical model; a radiation simulation human body model of patient individualization is constructed based on the medical image data, and then, three-dimensional dose distribution is obtained; and according to contouring of a gross tumor volume and normal structures, the equivalent biological dose is acquired by combining three-dimensional physical dose distribution and biological effect factors, and the dose volume histogram (DVH) of tumors and normal structures are obtained by calculation, so that a theoretical basis is provided for the design of novel targeted drugs and biological conversion of the accurate BNCT clinical treatment plan.

The invention relates to methods, systems and kits for determining therapeutic effectiveness or toxicity of cancer-treating compounds that incorporate into or bind to DNA. In particular, the invention is directed to methods, systems and kits for predicting a patient's treatment outcome after administration of a microdose of therapeutic composition to the patient or a sample from the patient. The methods provides physicians with a diagnostic tool to segregate cancer patients into differential populations that have a higher or lower chance of responding to a particular therapeutic treatment.

A method of measuring and identifying LSD and its major metabolite O-H-LSD, by obtaining a sample from an individual, and measuring, identifying, and quantifying LSD and O-H-LSD in the sample by performing a LC-MS/MS analysis. A method of treating and monitoring individuals taking LSD, by administering a microdose of LSD, a prodrug of LSD, or an analog of LSD to the individual, monitoring the individual by obtaining a sample from an individual and measuring and identifying the analytes in the sample by performing a LC-MS/MS analysis, and adjusting the microdose based on the amount of LSD quantified in the LC-MS/MS analysis. A method of adjusting dosing of LSD, by administering a microdose of LSD, a prodrug of LSD, or an analog of LSD to the individual, and adjusting the microdose based on blood concentration analytics.

A microdosing safety syringe. In order to provide a micro-dosage injector capable of destroying the needle and preventing the needle group from falling out of the syringe, the present invention is proposed, which consists of a syringe, a needle group and a piston group. There is a spigot; the front and rear ends of the needle group are hollow needle body and needle handle. Groove; the piston group is composed of a piston and a piston rod, and the piston is provided with a central through hole; the top surface and the outer circumference of the top of the piston rod are respectively provided with a thin rod with an arrowhead body on the top and an anti-penetration ring, and the middle outer circumference of the piston rod is provided with Locate bumps.